Smith FM - Search Results

1

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW. Charmsaz S, et al. Among authors: smith fm. Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6. Leukemia. 2017. PMID: 27922598

2

EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia.

Charmsaz S, Beckett K, Smith FM, Bruedigam C, Moore AS, Al-Ejeh F, Lane SW, Boyd AW. Charmsaz S, et al. Among authors: smith fm. PLoS One. 2015 Jun 17;10(6):e0130692. doi: 10.1371/journal.pone.0130692. eCollection 2015. PLoS One. 2015. PMID: 26083390 Free PMC article.

3

Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen.

Smith FM, Vearing C, Lackmann M, Treutlein H, Himanen J, Chen K, Saul A, Nikolov D, Boyd AW. Smith FM, et al. J Biol Chem. 2004 Mar 5;279(10):9522-31. doi: 10.1074/jbc.M309326200. Epub 2003 Dec 2. J Biol Chem. 2004. PMID: 14660665 Free article.

4

Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3.

Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M. Day B, et al. Among authors: smith fm. J Biol Chem. 2005 Jul 15;280(28):26526-32. doi: 10.1074/jbc.M504972200. Epub 2005 May 18. J Biol Chem. 2005. PMID: 15901737 Free article.

5

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.

Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW. Offenhäuser C, et al. Among authors: smith fm. Cancers (Basel). 2018 Dec 17;10(12):519. doi: 10.3390/cancers10120519. Cancers (Basel). 2018. PMID: 30562956 Free PMC article.

6

Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization.

Lackmann M, Oates AC, Dottori M, Smith FM, Do C, Power M, Kravets L, Boyd AW. Lackmann M, et al. Among authors: smith fm. J Biol Chem. 1998 Aug 7;273(32):20228-37. doi: 10.1074/jbc.273.32.20228. J Biol Chem. 1998. PMID: 9685371 Free article.

7

Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.

Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ. Stringer BW, et al. Among authors: smith fm. Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720. Oncotarget. 2016. PMID: 27083054 Free PMC article.

8

Eph/Ephrin membrane proteins: a mammalian expression vector pTIg-BOS-Fc allowing rapid protein purification.

Day BW, Smith FM, Chen K, McCarron JK, Herath NI, Lackmann M, Boyd AW. Day BW, et al. Among authors: smith fm. Protein Pept Lett. 2006;13(2):193-6. doi: 10.2174/092986606775101625. Protein Pept Lett. 2006. PMID: 16472084

9

The role of the Eph-ephrin signalling system in the regulation of developmental patterning.

Coulthard MG, Duffy S, Down M, Evans B, Power M, Smith F, Stylianou C, Kleikamp S, Oates A, Lackmann M, Burns GF, Boyd AW. Coulthard MG, et al. Int J Dev Biol. 2002;46(4):375-84. Int J Dev Biol. 2002. PMID: 12141423 Review.

10

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Pegg CL, Cooper LT, Zhao J, Gerometta M, Smith FM, Yeh M, Bartlett PF, Gorman JJ, Boyd AW. Pegg CL, et al. Among authors: smith fm. Sci Rep. 2017 Jul 26;7(1):6519. doi: 10.1038/s41598-017-06685-z. Sci Rep. 2017. PMID: 28747680 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page